Search Results
Feb 23, 2026, 16:40 ET FIBRA Prologis Announces Fourth Quarter and Full Year 2025 Earnings Results
trust ("FIBRA") status and tax structuring, (vi) availability of financing and capital, the levels of debt that we maintain and our credit ratings, (vii) risks related to our investments (viii) environmental uncertainties, including risks of natural disasters, (ix) risks related to global pandemics, and
More news about: FIBRA Prologis
Feb 23, 2026, 16:30 ET Keurig Dr Pepper Announces Updated Financing Plan for JDE Peet's Acquisition
completion of the acquisition of JDE Peet's and the subsequent separation of our beverage and coffee portfolios in the anticipated timeframe or at all, (vii) risks related to the receipt of regulatory approvals without unexpected delays or conditions, (viii) risks relating to our incurrence of significant
More news about: Keurig Dr Pepper
Feb 23, 2026, 07:21 ET Veris Residential to Be Acquired by Affinius Capital-Led Investor Consortium for $3.4 Billion in Cash
proposed transaction on the Company's ability to operate its business and retain and hire key personnel and to maintain favorable business relationships; (vii) the proposed transaction may result in the diversion of management's time and attention from ordinary course business operations to issues relating
More news about: Veris Residential, Inc.
Feb 21, 2026, 15:47 ET TTW Announces Top 50 Nightlife Travel Destinations in the World for 2026
unique "Sparty" culture in thermal baths. The city offers over 1,100 bars and pubs, with drinks ranging from $3.00 to $14.00. Districts V (Belváros) and VII are the heart of the action, where venues typically close between 4 AM and 6 AM. Safety is moderate to high, with police patrols, 24/7 CCTV, and private
More news about: Travel And Tour World
Feb 19, 2026, 19:21 ET FIBRA Prologis anuncia que Terrafina obtuvo autorización de la CNBV para la cancelación de la inscripción de sus CBFIs en el Registro Nacional de Valores
en bienes raíces ("FIBRA") y su estructura fiscal, (vi) disponibilidad de financiamiento y capital, niveles de deuda y calificaciones crediticias, (vii) riesgos relacionados con nuestras inversiones, (viii) incertidumbres ambientales, incluyendo riesgos de desastres naturales, y (ix) los factores adicionales
More news about: FIBRA Prologis
Feb 19, 2026, 19:14 ET FIBRA Prologis anuncia que Terrafina obtuvo autorización de la CNBV para la cancelación de la inscripción de sus CBFIs en el Registro Nacional de Valores
en bienes raíces ("FIBRA") y su estructura fiscal, (vi) disponibilidad de financiamiento y capital, niveles de deuda y calificaciones crediticias, (vii) riesgos relacionados con nuestras inversiones, (viii) incertidumbres ambientales, incluyendo riesgos de desastres naturales, y (ix) los factores adicionales
More news about: FIBRA Prologis
Feb 19, 2026, 18:24 ET FIBRA Prologis Announces that Terrafina Obtained CNBV Authorization for the Cancellation of the Registration of its CBFIs in the National Securities Registry
estate investment trust ("FIBRA") status and related tax structure; (vi) availability of financing and capital, debt levels and credit ratings; (vii) risks related to our investments; (viii) environmental uncertainties, including risks of natural disasters; and (ix) the additional factors described
More news about: FIBRA Prologis
Feb 19, 2026, 17:00 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer
2019;394(10212):1915–1928.3 Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol. 2010;21 Suppl 7:vii252–vii261. 4 Wise-Draper TM, Bahig H, Tonneau M, Karivedu V, Burtness B. Current Therapy for Metastatic Head and Neck Cancer: Evidence,
More news about: Johnson & Johnson
Feb 19, 2026, 16:46 ET FNF Reports Fourth Quarter and Full Year 2025 Financial Results
preceding two years;vii. Non-controlling interest on non-GAAP adjustments:
More news about: Fidelity National Financial, Inc.
Feb 19, 2026, 16:30 ET Select Medical Holdings Corporation Announces Results For Its Fourth Quarter and Year Ended December 31, 2025, Its 2026 Business Outlook, and Cash Dividend
was 10.5% both the fourth quarters ended December 31, 2025 and 2024. Certain critical illness recovery hospital key statistics are presented in table VII of this release for the fourth quarters ended December 31, 2025 and 2024.For the year ended December 31, 2025, revenue for the critical illness
More news about: Select Medical Holdings Corporation
Feb 19, 2026, 16:15 ET F&G Annuities & Life Reports Fourth Quarter and Full Year 2025 Results
that F&G does not wholly own; and(vii) Income taxes: the income tax impact related to the above-mentioned adjustments is measured using an effective tax rate, as appropriate by tax jurisdiction.
More news about: F&G Annuities & Life, Inc.
Feb 19, 2026, 09:00 ET Uranium Demand Continues to Rise as AI Power Demand Rewrites the Nuclear Playbook
effect of the announcement or pendency of the Proposed Business Combination on Eagle's business relationships, performance, and business generally; (vii) risks that the Proposed Business Combination disrupts current plans of Eagle and potential difficulties in its employee retention as a result of the
More news about: Equity Insider
Feb 19, 2026, 07:00 ET Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update
(vii) continued development of its pre-clinical
More news about: Insmed Incorporated
Feb 19, 2026, 06:55 ET Wheels Up Announces Fourth Quarter Results
divestitures, new debt or equity financings, refinancings of existing indebtedness, stock repurchases and commercial partnerships or arrangements; and (vii) the impacts of general economic and geopolitical conditions on Wheels Up's business and the aviation industry, including due to, among others, fluctuations
More news about: Wheels Up
Feb 19, 2026, 06:55 ET QUANTA SERVICES REPORTS FOURTH QUARTER AND FULL-YEAR 2025 RESULTS
currency translation losses recognized from substantial liquidation of certain foreign operations vary from period to period depending on activity; and (vii) income tax contingency releases vary period to period and depend on the level of reserves for uncertain tax positions and the expiration dates under
More news about: Quanta Services, Inc.
Feb 18, 2026, 16:05 ET Western Midstream Announces Record Fourth-Quarter and Full-Year 2025 Results
non-cash equity-based compensation expense, (iii) interest expense, (iv) income tax expense, (v) depreciation and amortization, (vi) impairments, and (vii) other expense (including lower of cost or market inventory adjustments recorded in cost of product), less (i) gain (loss) on divestiture and other,
More news about: Western Midstream Partners, LP
Feb 18, 2026, 16:05 ET GRAND CANYON EDUCATION, INC. REPORTS FOURTH QUARTER 2025 RESULTS
risks resulting from system disruptions, interruptions, or outages associated with our technology platforms or those of third-party service providers; (vii) the ability of our university partners' students to obtain federal Title IV funds, state financial aid, and private financing; (viii) potential damage
More news about: Grand Canyon Education, Inc.
Feb 18, 2026, 10:00 ET Grant & Eisenhofer P.A. and Levi & Korsinsky, LLP Announces Summary Notice of Pendency and Proposed Settlement of Stockholder Class Action for All Record and Beneficial Holders of Experience Investment Corp. Class A Common Stock Who Purchased, Acquired, or Held Such Securities at Any Time Between September 17, 2019 and May 3, 2021
EXCLUDED PERSONS, HAS, OR HAD AS OF THE REDEMPTION DEADLINE, A CONTROLLING INTEREST; (V) KSL CAPITAL PARTNERS LLC; (VI) STEELE EXPCO HOLDINGS, INC.; (VII) ROSS AVIATION LLC; AND (VIII) THE LEGAL REPRESENTATIVES, AGENTS, AFFILIATES, HEIRS, ESTATES, SUCCESSORS, OR ASSIGNS OF ANY SUCH EXCLUDED PERSONS
More news about: Grant & Eisenhofer P.A. and Levi & Korsinsky, LLP
Feb 18, 2026, 08:00 ET Ginkgo Bioworks and Invaio Sciences Enter Collaboration to Develop Manufacturing Technology for Peptide-based Agricultural Products
biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of
More news about: Ginkgo Bioworks
Feb 17, 2026, 11:08 ET Beyond Tech: The Hidden Winners of the AI Energy Boom
effect of the announcement or pendency of the Proposed Business Combination on Eagle's business relationships, performance, and business generally; (vii) risks that the Proposed Business Combination disrupts current plans of Eagle and potential difficulties in its employee retention as a result of the
More news about: USA News Group
Feb 17, 2026, 08:00 ET Danaher To Acquire Masimo Corporation
circumstance that could give rise to the termination of the merger agreement, including in circumstances which would require Masimo to pay a termination fee; (vii) the effect of the announcement or pendency of the transactions contemplated by the merger agreement on Masimo's or Danaher's ability to retain and hire
More news about: Danaher Corporation
Feb 17, 2026, 07:09 ET WBD Files Definitive Proxy Statement and Schedules Special Meeting for March 20, 2026, to Approve the WBD-Netflix Transaction
directors; (vi) the risk that disruptions from the proposed transaction will harm Netflix's or WBD's business, including current plans and operations; (vii) the ability of Netflix or WBD to retain and hire key personnel; (viii) potential adverse reactions or changes to business relationships resulting from
More news about: Netflix, Inc.
Feb 17, 2026, 07:03 ET WBD Files Definitive Proxy Statement and Schedules Special Meeting for March 20, 2026, to Approve the WBD-Netflix Transaction
directors; (vi) the risk that disruptions from the proposed transaction will harm Netflix's or WBD's business, including current plans and operations; (vii) the ability of Netflix or WBD to retain and hire key personnel; (viii) potential adverse reactions or changes to business relationships resulting from
More news about: Netflix, Inc.
Feb 17, 2026, 07:00 ET Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis
markets; (vi) a Fast Track designation does not increase the likelihood that rezpegaldesleukin will receive marketing approval in the United States; (vii) patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual
More news about: Nektar Therapeutics
Feb 17, 2026, 06:50 ET Labcorp Announces 2025 Fourth Quarter and Full Year Results
interpretation and application of such laws and regulations; (vi) customer purchasing decisions, including changes in payer regulations or policies; (vii) adverse actions of governmental and third-party payers; (viii) changes in testing guidelines or recommendations; (ix) the impact of global geopolitical
More news about: Labcorp Holdings Inc